Regulation of human nerve growth factor-related G protein-coupled receptor

An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:2.

A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

• culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
• and
• isolating the polypeptide.

A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

• hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:1 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
• and
• detecting the hybridization complex.

A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:

• contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
• and
• detecting the reagent-polypeptide complex.

A method of screening for agents which modulate an activity of a human NGFR-GPCR, comprising the steps of:

• contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO:1;
• and
• detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human NGFR-GPCR.

A method of reducing activity of a human NGFR-GPCR, comprising the step of:

• contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1, whereby the activity of a human NGFR-GPCR is reduced.

A pharmaceutical composition, comprising:

• a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2;
• and
• a pharmaceutically acceptable carrier.

A pharmaceutical composition, comprising:

• a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1;
• and
• a pharmaceutically acceptable carrier.

A pharmaceutical composition, comprising:

• an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2;
• and
• a pharmaceutically acceptable carrier.

A method of treating a central nervous system disease, comprising the step of:

• administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human NGFR-GPCR, whereby symptoms of the central nervous system disease are ameliorated.

A method of treating a peripheral nervous system disease, comprising the step of:

• administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human NGFR-GPCR, whereby symptoms of the peripheral nervous system disease are ameliorated.

A method of treating urinary incontinence, comprising the step of:

• administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human NGFR-GPCR, whereby symptoms of the urinary incontinence are ameliorated.